<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341779</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00007544</org_study_id>
    <secondary_id>R01AI147752</secondary_id>
    <nct_id>NCT04341779</nct_id>
  </id_info>
  <brief_title>Simplifying Treatment and Monitoring for HIV (STREAM HIV)</brief_title>
  <official_title>Simplifying Treatment and Monitoring for HIV (STREAM HIV): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for the AIDS Programme of Research in South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine the clinical efficacy and cost effectiveness of implementing an&#xD;
      integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence&#xD;
      testing and POC viral load (VL) monitoring in improving ART adherence, maintaining durable VL&#xD;
      suppression, and improving retention in care among HIV-positive individuals initiating&#xD;
      first-line tenofovir disoproxil fumarate (TDF)-based ART in South Africa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a two-arm, open-label, randomized controlled superiority trial at an HIV&#xD;
      clinic in Durban. HIV-positive individuals aged 16 years and above, who are initiating a&#xD;
      tenofovir-based, first-line ART will be randomized to receive POC VL testing and POC TFV&#xD;
      adherence testing, versus standard-of-care (SoC) viral load testing. The schedule for VL&#xD;
      testing and management of VL test results will follow South African guidelines for HIV VL&#xD;
      testing after ART initiation. 540 participants will be randomized (1:1) at ART initiation&#xD;
      into the intervention arm (routine POC TFV adherence testing with POC VL monitoring) or the&#xD;
      standard-of-care (SoC) arm (no objective TFV adherence testing and SoC VL monitoring).&#xD;
&#xD;
      Participants will be followed to compare concentrations between study arms at 24 weeks after&#xD;
      ART initiation and a composite outcome of VL suppression and retention in care between the&#xD;
      study arms at 72 weeks after ART initiation. The study will use process evaluation data,&#xD;
      interviews and focus groups with patients and staff to assess implementation of the POC&#xD;
      assays. Micro-costing will be conducted to estimate intervention costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean tenofovir diphosphate concentration levels in dried blood spots</measure>
    <time_frame>24 weeks after ART initiation</time_frame>
    <description>We will measure tenofovir-diphosphate concentrations in 3mm dried blood spots using liquid chromatography/tandem mass spectrometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined measure of virological suppression and retention in care (binary)</measure>
    <time_frame>72 weeks after ART initiation</time_frame>
    <description>We will measure viral load by a laboratory-based reference assay, performed by the South African National Health Laboratory Services. Viral suppression will be defined as a viral load &lt;200 copies/mL. Retention in care will be defined as having collected ART from the study clinic within 8 weeks of study exit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined measure of viral suppression and retention in care (binary)</measure>
    <time_frame>24 weeks after ART initiation</time_frame>
    <description>We will measure viral load by a laboratory-based reference assay, performed by the South African National Health Laboratory Services. Viral suppression will be defined as a viral load &lt;200 copies/mL. Retention in care will be defined as having collected ART from the study clinic within 8 weeks of their 6-month study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tenofovir-diphosphate concentration in dried blood spots (continuous)</measure>
    <time_frame>72 weeks after ART initiation</time_frame>
    <description>We will measure tenofovir-diphosphate concentrations in 3mm dried blood spots using liquid chromatography/tandem mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of point-of-care tenofovir and viral load testing</measure>
    <time_frame>24 and 72 weeks after ART initiation</time_frame>
    <description>We will assess acceptability of point-of-care tenofovir and viral load testing by conducting semi-structured in-depth interviews and focus group discussions with study participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of providing routine point-of-care tenofovir and viral load testing as compared to standard-of-care viral load monitoring</measure>
    <time_frame>24 and 72 weeks after ART initiation</time_frame>
    <description>We will conduct a micro-costing of the costs associated with point-of-care tenofovir and viral load testing and will estimate the cost-effectiveness of the intervention using an existing individual-based, stochastic HIV model for KwaZulu-Natal for simulating health and economic outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Point-of-care adherence testing and Point-of-care viral load testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-of-care arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No adherence testing and lab-based viral load testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Point-of-care viral load testing and tenofovir adherence testing</intervention_name>
    <description>Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  â‰¥16 years old&#xD;
&#xD;
          -  Initiating a TDF-based, first-line ART regimen&#xD;
&#xD;
          -  Do not self-report being on an ART regimen in the prior month&#xD;
&#xD;
          -  Willing/able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not plan to continue receiving HIV care at the CDC Clinic&#xD;
&#xD;
          -  Per the decision or opinion of the PI (for example, a clinically significant acute or&#xD;
             chronic medical condition or circumstances that would make the patient unsuitable for&#xD;
             participation or jeopardize the safety or rights of the participant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Drain, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nigel Garett, MBBS, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fathima Sayed</last_name>
    <phone>+27316550611</phone>
    <email>fathima.sayed@caprisa.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zarna Marfatia</last_name>
    <phone>+12065203800</phone>
    <email>zarnam@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fathima Sayed</last_name>
      <phone>+27312604374</phone>
      <email>fathima.sayed@caprisa.org</email>
    </contact>
    <contact_backup>
      <last_name>Nigel Garrett, MBBS, PhD</last_name>
      <phone>+27312604453</phone>
      <email>nigel.garrett@caprisa.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nigel Garrett, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Paul Drain</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Point-of-care test</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Adherence</keyword>
  <keyword>HIV viral load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data from the study will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following publication of primary results.</ipd_time_frame>
    <ipd_access_criteria>De-identified data generated under this project will be administered in accordance with University of Washington, CAPRISA, and NIH policies, including the NIH Data Sharing Policy and Implementation Guidance of March 5, 2003.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

